Crescent Biopharma (CBIO) Non-Current Assets (2013 - 2026)
Crescent Biopharma (CBIO) reported Non-Current Assets of $3.6 million for Q1 2026, down 1.95% on a QoQ basis from $3.6 million in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of Non-Current Assets data on file, last reported at $3.6 million in Q1 2026.
- Quarterly Non-Current Assets changed N/A year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.1 million (up 889.53% YoY) and the FY2025 annual result came in at $3.6 million, up 347.48% from the prior year.
- Non-Current Assets retreated to $3.6 million in Q1 2026 per CBIO's latest filing, from $3.6 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $4.0 million in Q1 2022 and bottomed at $52320.0 in Q3 2024.
- The 5-year median for Non-Current Assets is $1.5 million (2023), against an average of $2.0 million.
- The widest annual swing landed in 2024, when Non-Current Assets slumped 95.61%; it then surged 6983.33% in 2025.
- Tracing CBIO's Non-Current Assets over 5 years: stood at $1.1 million in 2022, then jumped by 39.22% to $1.5 million in 2023, then tumbled by 46.71% to $813000.0 in 2024, then surged by 347.48% to $3.6 million in 2025, then retreated by 1.95% to $3.6 million in 2026.
- Per Business Quant, the three latest CBIO Non-Current Assets figures stand at $3.6 million (Q1 2026), $3.6 million (Q4 2025), and $3.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 3.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.57 Mn |
| Dec 31, 2025 | 3.64 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 3.21 Mn |
| Dec 31, 2024 | 813,000.00 |
| Sep 30, 2024 | 52,320.00 |
| Jun 30, 2024 | 561,314.00 |
| Mar 31, 2024 | 937,520.00 |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.19 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 835,123.00 |
| Dec 31, 2022 | 1.10 Mn |
| Sep 30, 2022 | 2.11 Mn |
| Jun 30, 2022 | 3.78 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | 3.56 Mn |
| Sep 30, 2021 | 3.81 Mn |
| Jun 30, 2021 | 4.06 Mn |
| Mar 31, 2021 | 4.31 Mn |
| Dec 31, 2020 | 4.56 Mn |
| Sep 30, 2020 | 4.78 Mn |
| Jun 30, 2020 | 4.99 Mn |
| Mar 31, 2020 | 5.22 Mn |
| Dec 31, 2019 | 5.44 Mn |
| Sep 30, 2019 | 5.66 Mn |
| Jun 30, 2019 | 5.87 Mn |
| Mar 31, 2019 | 6.05 Mn |
| Dec 31, 2018 | 2.57 Mn |
| Sep 30, 2018 | 2.74 Mn |
| Jun 30, 2018 | 2.78 Mn |
| Mar 31, 2018 | 1.31 Mn |
| Dec 31, 2017 | 1.36 Mn |
| Sep 30, 2017 | 1.93 Mn |
| Jun 30, 2017 | 1.97 Mn |
| Mar 31, 2017 | 1.89 Mn |
| Dec 31, 2016 | 1.87 Mn |
| Sep 30, 2016 | 1.49 Mn |
| Jun 30, 2016 | 1.24 Mn |
| Mar 31, 2016 | 1.19 Mn |
| Dec 31, 2015 | 1.22 Mn |
| Sep 30, 2015 | 1.26 Mn |
| Jun 30, 2015 | 1.28 Mn |
| Mar 31, 2015 | 1.12 Mn |
| Dec 31, 2014 | 1.15 Mn |
| Sep 30, 2014 | 481,853.00 |
| Jun 30, 2014 | 420,640.00 |
| Mar 31, 2014 | 379,099.00 |
| Dec 31, 2013 | 399,799.00 |